Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.

Haitao ChenRong NaVignesh T PackiamCarly A ConranDeke JiangSha TaoHongjie YuXiaoling LinWei MengS Lilly ZhengCharles B BrendlerBrian T HelfandJianfeng Xu

Published in: The Prostate (2017)

Risk assessment using currently available SNPs is justified. Multiple GRS values from evolving sets of SNPs provide a valuable tool for better refining risk.

Keyphrases

genome wide
risk assessment
prostate cancer
genome wide association
dna methylation
human health
phase iii
heavy metals
phase ii
randomized controlled trial
benign prostatic hyperplasia
gene expression
climate change